Turning Point Shares Plunge After Highlighting Updated Data From Lead Program In Pretreated Lung Cancer Patients

Turning Point Therapeutics Inc TPTX has announced additional preliminary data from ongoing trials of lead drug candidate repotrectinib and elzovantinib (TPX-0022).
The data were presented at the Virtual International Conference on Molecular Targets and Cancer Therapeutics.
Repotrectinib demonstrated clinical activity across multiple ROS1+ TKI-pretreated NSCLC Cohorts, with confirmed objective response rates (cORR) of 30%-39% in the TRIDENT-1 Study.
Repotrectinib showed a cORR of 53% in ROS1+ TKI-Pretreated NSCLC Patients with G2032R Solvent Front Mutation.
At the anticipated meeting with the FDA in 1H of 2022, Turning Point plans to discuss available BICR data in at least 50 patients from the ROS1-positive TKI-pretreated NSCLC cohorts of the study.
Elzovantinib (TPX-0022) achieved cORR of 36% and 33%, respectively, in MET TKI-Naïve NSCLC and Gastric / Gastroesophageal Junction Cancer Patients Harboring Genetic Alterations in MET in SHIELD-1 Study.
Related: Turning Point's TPX-0022 In Gastric Cancer Gets Orphan Drug Designation In US.
For Elzovantinib, based on the FDA feedback, the Company plans to revise SHIELD-1 into a potentially registrational Phase 1/2 study and initiate the Phase 2 portion of SHIELD-1 in 2022, pending FDA feedback on data from the intermediate dose level.
Price Action: TPTX shares are down 15.3% at $51.42 during the market session on the last check Thursday.